← Back to Search

Monoclonal Antibodies

nL-SAA1-01 for Amyloidosis

Phase 1
Waitlist Available
Research Sponsored by Nelson Leung, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Measurable disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to determine if injecting nL-SAA1-01 under the skin is safe and effective for patients with AA Amyloidosis."

Who is the study for?
This trial is for patients with AA Amyloidosis. Specific eligibility details are not provided, but typically participants must meet certain health criteria and may be required to have a confirmed diagnosis of AA Amyloidosis.
What is being tested?
The study is testing the safety and effectiveness of nL-SAA1-01, which is administered through an injection under the skin (subcutaneous) to treat AA Amyloidosis.
What are the potential side effects?
Potential side effects are not listed, but subcutaneous injections can sometimes cause pain at the injection site, swelling, redness, and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer can be measured by tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events and/or serious adverse events
Secondary study objectives
Change in kidney function
Change in quality of life - emotional well-being
Change in quality of life - intellectual well-being
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: nL-SAA1-01Experimental Treatment1 Intervention
Subject will receive subcutaneous injection of nL-SAA1-01

Find a Location

Who is running the clinical trial?

Nelson Leung, MDLead Sponsor
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top